Results 61 to 70 of about 9,572 (201)

Understanding CPVT pathogenic mechanisms based on mutation location within RyR2: towards personalized medicine?

open access: yes
The Journal of Physiology, EarlyView.
Jean‐Pierre Benitah   +2 more
wiley   +1 more source

Extrasystoles on 24‐h Holter Monitoring During the First Year of Life

open access: yesActa Paediatrica, Volume 115, Issue 2, Page 370-377, February 2026.
ABSTRACT Aim To assess the natural course of extrasystoles and their association with tachyarrhythmias on 24‐h Holter monitoring during the first year of life. Methods A retrospective chart review was performed among newborns referred for 24‐h Holter monitoring at Tampere University Hospital from 2011 to 2017.
Asta Uusitalo   +5 more
wiley   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang   +5 more
wiley   +1 more source

A Rational Approach to Pharmacotherapy in Pregnancy

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Most pregnant individuals are exposed to at least one medication, whether prescription or over the counter, during pregnancy. Despite the ubiquity of medication use in pregnancy, there remains no standardized framework to guide clinicians in selecting the most appropriate pharmacotherapy that balances maternal needs with fetal safety. This gap
Gregory W. Kirschen   +2 more
wiley   +1 more source

Cardiogenic Shock in a Hemodialyzed Patient on Flecainide: Treatment with Intravenous Fat Emulsion, Extracorporeal Cardiac Life Support, and CytoSorb® Hemoadsorption

open access: yesCase Reports in Cardiology, 2019
A 67-year-old woman with a history of end-stage renal disease on hemodialysis received a therapeutic dose (150 mg daily) of flecainide for three weeks.
Nicolas De Schryver   +3 more
doaj   +1 more source

Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation

open access: yesBMC Cardiovascular Disorders, 2017
Background Atrial fibrillatory cycle length has been considered one of the indices of atrial electrical remodelling during atrial fibrillation (AF), which can be assessed from surface ECG by computer-assisted calculation of atrial fibrillatory rate (AFR).
Eva Z. Hesselkilde   +7 more
doaj   +1 more source

Results of a Survey “Ethacizine evaluation for acute and chronic treatment of atrial fibrillation in real practice: Ukrainian national survey (ETERNITY)”

open access: yesСучасні медичні технології
The aim of the study: based on a survey of physicians, the study aims to identify the real clinical practices regarding the use of class IC antiarrhythmic drugs in Ukraine, particularly ethacizine, for restoring sinus rhythm in paroxysmal and persistent ...
N. M. Sydorova, M. Yu. Kolesnyk
doaj   +1 more source

Home - About - Disclaimer - Privacy